Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.
Jeffrey S BergerRoger SeheultFrançois LalibertéConcetta CriveraDominique LejeuneYongling XiaoJeff ScheinPatrick LefebvreScott KaatzPublished in: Research and practice in thrombosis and haemostasis (2017)
Continued rivaroxaban treatment beyond an initial 3- or 6-month treatment period significantly lowered the risk of recurrent VTE without a significant increase of major bleeding, compared to treatment discontinued at 3 or 6 months.